Saturday, September 26, 2015

Availability of Medical Abortion in the U.S. Continues to Provide Women Safe Alternative, 15-Years after FDA Approval

WASHINGTON--(BUSINESS WIRE)--This September marks the 15-year anniversary of the U.S. Buy Aldara (Imiquimod) with free prescription Food and Drug Administration (FDA) s approval of the use of Mifepristone (also known as RU-486 or the "abortion pill"). About Zantac (Ranitidine) without prescription Mifepristone is the first and only FDA approved medication to provide women with a safe and effective non-surgical option to end an early pregnancy. “Medication abortion is an empowering, private, and non-invasive procedure that puts the control back in the woman’s hands. About Super Active Pack-40 () without prescription Carafem is proud to focus on the availability of the abortion pill along with a variety of birth control options to provide women choices and support their decisions regarding the timing and spacing of their children,” says Melissa Grant VP of Carafem. Buy Flutex “Women are given Mifepristone in our health center, to be followed by another medication called Misoprostol, usually taken at home the same day or up to 72 hours later. Inderal La (Propranolol) with no prescription Having options for how and when to use these medications allows a woman more flexibility and control around when and where she experiences the abortion process. Buy CoQ10 Supplements online Medication abortion does not require surgery or anesthesia.” The proportion of women in the United States deciding to end a pregnancy by medication has been steadily growing since Mifepristone’s approval. http://doctor-answers.blogspot.com/ Since 2000, more than 2 million women in the United States have chosen medication abortion for ending an early pregnancy. There is overwhelming evidence that medication abortion is safe for virtually all women. Never before has abortion been safer, less invasive and more affordable than with medication abortion and Carafem focuses on the provision of this method for early abortion care. By providing same-day appointments, one-on-one private visits with a knowledgeable clinician, financial assistance, and visits that routinely last no more than an hour, Carafem is responding to a critical need in women’s reproductive healthcare. Medically unnecessary restrictions have contributed to the abortion pill not being as widely available to women as it could be. The reality is that these regulations do nothing to make abortion safer- but they make it more costly and less available. “Carafem is proud to ensure that women are aware of all of their reproductive health care options through education in our health centers and through our honest and cutting-edge advertising campaigns. Carafem aims to lift the stigma that surrounds this common medical procedure,” adds Grant. On the 15th anniversary of Mifepristone’s approval in the U.S., Carafem aims to deflate negativity and increase awareness of something that is, and has been, common in our society. In fact, 1 in 3 women will choose to have an abortion during her reproductive lifetime. This statistic offers cultural validation for updating the conversation and highlights the importance of access to quality health care.

Friday, September 11, 2015

Biogen Prices $6.0 Billion of Senior Unsecured Notes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the pricing of four series of senior unsecured notes for an aggregate principal amount of $6.0 billion. Buy Zofran (Ondansetron) without prescription The notes will mature as follows: $1.50 billion will mature on September 15, 2020 and will bear interest at an annual rate of 2.900% $1.00 billion will mature on September 15, 2022 and will bear interest at an annual rate of 3.625% $1.75 billion will mature on September 15, 2025 and will bear interest at an annual rate of 4.050% $1.75 billion will mature on September 15, 2045 and will bear interest at an annual rate of 5.200% The offering is expected to close on September 15, 2015, subject to customary closing conditions. Biogen intends to use the net proceeds from this offering, together with cash on hand, to fund share repurchases of its common stock under the company’s previously authorized $5.0 billion share repurchase program, for working capital and other general corporate purposes. Goldman, Sachs & Co. Azulfidine (Sulfasalazine) with no prescription and Merrill Lynch, Pierce, Fenner & Smith Incorporated are acting as joint book-running managers and representatives of the several underwriters. Avapro (Irbesartan) with free Rx A copy of the preliminary prospectus supplement and the accompanying base prospectus, which is filed as part of Biogen’s effective shelf registration statement on Form S-3 filed on September 8, 2015 (File No. About Felogard without prescription 333-206799), may be obtained from either of the representatives by calling Goldman, Sachs & Co. About Maxalt (Rizatriptan) toll-free at 1 (866) 471-2526 or Merrill Lynch, Pierce, Fenner & Smith Incorporated toll-free at 1 (800) 294-1322. An electronic copy of the prospectus supplement and the accompanying base prospectus may also be obtained at no charge at the Securities and Exchange Commission’s website at .sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or other jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction, where the offer, solicitation or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Buy Cat’s Claw online The offering of the notes may be made only by means of a prospectus supplement and the accompanying base prospectus. About BiogenThrough cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. http://future-pharmaceuticals.blogspot.com Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. Biogen Safe Harbor StatementThis press release contains forward-looking statements that involve risks and uncertainties, including statements about the expected use of proceeds and timing of completion of the offering. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. The offering may also be adversely affected by market conditions, adverse changes to Biogen’s business or prospects, and the other risks and uncertainties that are described in Biogen’s filings with the Securities and Exchange Commission. These statements are based on current beliefs and expectations and speak only as of the date of this press release. Biogen does not undertake any obligation to publicly update any forward-looking statements.

Wednesday, September 2, 2015

Eosinophilic Esophagitis Pipeline Review, H2 2015 - 7 Companies & 8 Drug Profiles

. About Etoricoxib with free prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/bgmx8f/eosinophilic) has announced the addition of the "Eosinophilic Esophagitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. About Noroxin (Norfloxacin) Buy Vermox (Mebendazole) with free Rx It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Buy Breast Enhancement online Buy Cialis Daily (Tadalafil) with free prescription It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development Allergan Plc DBV Technologies S.A. Dr. http://medical-questions-answers.blogspot.com Buy Indocin (Indomethacin) Falk Pharma GmbH Novartis AG Receptos, Inc. Regeneron Pharmaceuticals, Inc. Shire Plc Drug Profiles Allergen for Milk Allergy budesonide budesonide dectrekumab dupilumab EUR-1100 Qi-406 RPC-4046 For more information visit .researchandmarkets.com/research/bgmx8f/eosinophilic